Miyamoto K K, McSherry S A, Dent G A, Sar M, Wilson E M, French F S, Sharief Y, Mohler J L
Department of Surgery Division of Urology, University of North Carolina, Chapel, Hill.
J Urol. 1993 May;149(5):1015-9. doi: 10.1016/s0022-5347(17)36284-5.
The role of the androgen receptor in the development and progression of prostatic carcinoma has not been defined. The development of androgen receptor antibodies has provided new opportunities for direct immunohistochemical analysis. We compared the androgen receptor staining characteristics of fresh human prostatic carcinoma with benign prostatic hyperplasia (BPH) using an avidin-biotin complex method. Cancer and BPH obtained from the same radical retropubic prostatectomy specimen in 10 prostate cancer patients (68.5 +/- 7.3 years old standard deviation) and BPH from 10 noncancer patients (71.5 +/- 7.7 years old) were incubated with AR52, a rabbit polyclonal antibody against a synthetic androgen receptor peptide. Nuclei within each section were graded for intensity of androgen receptor staining (0-absent, 1-weak, 2-moderate or 3-strong) and the percentage (0 to 100%) of nuclei sampled staining at each of these intensity levels was determined. A total intensity score (0 to 300) was the summation of the products of each intensity score (0 to 3) and their corresponding percentages. Cancer sections (166 +/- 69) stained less intensely and more heterogeneously than BPH in cancer patients (246 +/- 41, Student's t test p < 0.05) and noncancer patients (225 +/- 39, p < 0.05). The decreased intensity and greater heterogeneity of androgen receptor staining in cancer tissue may implicate a quantitative or functional difference in androgen receptor between prostatic carcinoma and BPH.
雄激素受体在前列腺癌发生发展中的作用尚未明确。雄激素受体抗体的研发为直接免疫组织化学分析提供了新机遇。我们采用抗生物素蛋白-生物素复合物法，比较了新鲜人前列腺癌组织与良性前列腺增生（BPH）组织中雄激素受体的染色特征。取自10例前列腺癌患者（年龄标准差68.5±7.3岁）同一耻骨后前列腺根治性切除术标本的癌组织和BPH组织，以及取自10例非癌患者（年龄标准差71.5±7.7岁）的BPH组织，与AR52（一种针对合成雄激素受体肽的兔多克隆抗体）一起孵育。对每个切片中的细胞核进行雄激素受体染色强度分级（0-无，1-弱，2-中等或3-强），并确定在每个强度水平染色的取样细胞核百分比（0至100%）。总强度评分（0至300）为每个强度评分（0至3）与其相应百分比的乘积之和。癌组织切片（166±69）的染色强度低于癌患者（246±41，Student t检验p<0.05）和非癌患者（225±39，p<0.05）的BPH组织，且更为不均一。癌组织中雄激素受体染色强度降低和不均一性增加可能意味着前列腺癌与BPH组织中雄激素受体在数量或功能上存在差异。
